Accent Capital Management’s Blueprint Medicines BPMC Stock Holding History

Accent Capital Management’s Portfolio BPMC Stock Details BPMC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-80	Closed	-$10.3K	–	382
2025 Q2	$10.3K	Hold	80	–	–	﹤0.01%	222
2025 Q1	$7.08K	Buy	+80	New	+$7.8K	﹤0.01%	222

Other funds holding BPMC

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Accent Capital Management's BPMC Position: Q3 2025 in Review

Accent Capital Management sold out of Blueprint Medicines (BPMC) in Q3 2025, closing a stake of 80 shares — an estimated $10.3K sold.

Accent Capital Management first reported a position in BPMC in Q1 2025 and held it in 2 quarters. The position peaked at $10.3K in Q2 2025. 5 funds tracked by Wall St. Rank hold BPMC as of Q3 2025.

Accent Capital Management reported no remaining Blueprint Medicines position as of Q3 2025 after selling out during the quarter.
Accent Capital Management sold 80 Blueprint Medicines shares in Q3 2025, an estimated $10.3K.
Accent Capital Management first reported a position in Blueprint Medicines in Q1 2025 and held it in 2 quarters.
Accent Capital Management's Blueprint Medicines position peaked at $10.3K in Q2 2025.
5 funds tracked by Wall St. Rank held Blueprint Medicines as of Q3 2025.

Based on Accent Capital Management's 13F filing for Q3 2025, filed 12 Nov 2025.